{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.6","upperLimit":"72.2","value":"56.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"}],"units":"Participants"}],"description":"The percentage of participants with either Complete Response (CR) or Partial Response (PR) in their disease burden based upon the rules of the Response Evaluation Criteria in Solid Tumors (RECIST). A participant with of all of the lesions disappearing is a CR. A participant with at least a 30 percent decrease in the measured lesions is a PR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Paclitaxel 135 mg/m\\^2 intravenous (IV) over 1 hour; Gemcitabine 900 mg/m\\^2 IV over 90 minutes; Doxorubicin 40 mg/m\\^2 IV over 20 minutes; treatment may repeat every 2 weeks for up to nine courses. Subcutaneous Injection of Pegfilgrastim on day 1 or 2 of each course, after chemotherapy.","id":"OG000","title":"Gemcitabine, Paclitaxel and Doxorubicin"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 12 weeks, or following completion 6 cycles of chemotherapy, respectively; the best response achieved within 6 cycles of starting chemotherapy used to calculate response rate.","title":"Objective Response Rate","type":"PRIMARY","unitOfMeasure":"percentage of participants"}